| These highlights do not include all the information needed to use HADLIMA safely and effectively. See full prescribing information for HADLIMA. HADLIMA (adalimumab-bwwd) injection, for subcutaneous use Initial U.S. Approval: 2019 HADLIMA (adalimumab-bwwd) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences betwee | A-S Medication Solutions | 20260514 | 3 |
| These highlights do not include all the information needed to use ABRILADA safely and effectively. See full prescribing information for ABRILADA. ABRILADA™ (adalimumab-afzb) injection, for subcutaneous use Initial U.S. Approval: 2019 ABRILADA (adalimumab-afzb) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences b | Pfizer Laboratories Div Pfizer Inc | Wyeth BioPharma Division of Wyeth Pharmaceuticals LLC | Pfizer Ireland Pharmaceuticals Unlimited Company | Pfizer Manufacturing Belgium NV | 20260506 | 8 |
| These highlights do not include all the information needed to use AMJEVITA safely and effectively. See full prescribing information for AMJEVITA. AMJEVITA ® (adalimumab-atto) injection, for subcutaneous use Initial U.S. Approval: 2016 AMJEVITA (adalimumab-atto) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product known as a reference product, and that there are no clinically meaningful differences b | Amgen, Inc | Amgen Manufacturing Limited LLC | Bioreliance Corporation | 20260310 | 35 |
| These highlights do not include all the information needed to use AMJEVITA safely and effectively. See full prescribing information for AMJEVITA. AMJEVITA ® (adalimumab-atto) injection, for subcutaneous use Initial U.S. Approval: 2016 AMJEVITA (adalimumab-atto) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product known as a reference product, and that there are no clinically meaningful differences b | Nuvaila Limited | Amgen, Inc | 20260308 | 6 |
| These highlights do not include all the information needed to use ADALIMUMAB-RYVK safely and effectively. See full prescribing information for ADALIMUMAB-RYVK . ADALIMUMAB-RYVK injection, for subcutaneous use Initial U.S. Approval: 2024 This product is SIMLANDI ® (adalimumab-ryvk). SIMLANDI ® (adalimumab-ryvk) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and th | Teva Pharmaceuticals USA, Inc. | 20260303 | 1 |
| These highlights do not include all the information needed to use CYLTEZO safely and effectively. See full prescribing information for CYLTEZO. CYLTEZO ® (adalimumab-adbm) injection, for subcutaneous use Initial U.S. Approval: 2017 CYLTEZO (adalimumab-adbm) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences betw | Boehringer Ingelheim Pharmaceuticals, Inc. | 20260303 | 17 |
| These highlights do not include all the information needed to use IDACIO safely and effectively. See full prescribing information for IDACIO. IDACIO® (adalimumab-aacf) injection, for subcutaneous use Initial U.S. Approval: 2022 IDACIO® (adalimumab-aacf) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between | Fresenius Kabi USA, LLC | Fresenius Kabi Austria | Merck Serono SPA | 20260130 | 7 |
| These highlights do not include all the information needed to use ADALIMUMAB-RYVK safely and effectively. See full prescribing information for ADALIMUMAB-RYVK . ADALIMUMAB-RYVK injection, for subcutaneous use Initial U.S. Approval: 2024 Adalimumab-ryvk is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between t | Quallent Pharmaceuticals Health LLC | Alvotech HF | 20260119 | 12 |
| These highlights do not include all the information needed to use ADALIMUMAB-AACF safely and effectively. See full prescribing information for ADALIMUMAB-AACF. ADALIMUMAB-AACF injection, for subcutaneous use Initial U.S. Approval: 2022 This product is IDACIO ® (adalimumab-aacf). IDACIO ® (adalimumab-aacf) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that th | Fresenius Kabi USA, LLC | Fresenius Kabi Austria | Merck Serono SPA | 20260108 | 6 |
| These highlights do not include all the information needed to use ADALIMUMAB-RYVK safely and effectively. See full prescribing information for ADALIMUMAB-RYVK . ADALIMUMAB-RYVK injection, for subcutaneous use Initial U.S. Approval: 2024 This product is SIMLANDI ® (adalimumab-ryvk). SIMLANDI ® (adalimumab-ryvk) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and th | Teva Pharmaceuticals USA, Inc. | 20251231 | 7 |
| These highlights do not include all the information needed to use HUMIRA safely and effectively. See full prescribing information for HUMIRA. HUMIRA ® (adalimumab) injection, for subcutaneous use Initial U.S. Approval: 2002 | Cordavis Limited | 20251223 | 4 |
| These highlights do not include all the information needed to use HUMIRA safely and effectively. See full prescribing information for HUMIRA. HUMIRA ® (adalimumab) injection, for subcutaneous use Initial U.S. Approval: 2002 | AbbVie Inc. | 20251223 | 2154 |
| These highlights do not include all the information needed to use SIMLANDI safely and effectively. See full prescribing information for SIMLANDI. SIMLANDI ® (adalimumab-ryvk) injection, for subcutaneous use Initial U.S. Approval: 2024 SIMLANDI (adalimumab-ryvk) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences | Teva Pharmaceuticals USA, Inc. | 20251222 | 24 |
| These highlights do not include all the information needed to use ADALIMUMAB-ADBM safely and effectively. See full prescribing information for ADALIMUMAB-ADBM. ADALIMUMAB-ADBM injection, for subcutaneous use Initial U.S. Approval: 2017 This product is CYLTEZO ® (adalimumab-adbm). CYLTEZO (adalimumab-adbm) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that th | Boehringer Ingelheim Pharmaceuticals, Inc. | 20251112 | 5 |
| These highlights do not include all the information needed to use YUSIMRY safely and effectively. See full prescribing information for YUSIMRY. YUSIMRY (adalimumab-aqvh) injection, for subcutaneous use Initial U.S. Approval: 2021 YUSIMRY (adalimumab-aqvh) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences betwee | Meitheal Pharmaceuticals Inc. | 20251031 | 6 |
| These highlights do not include all the information needed to use ADALIMUMAB-AATY safely and effectively. See full prescribing information for ADALIMUMAB-AATY. ADALIMUMAB-AATY injection, for subcutaneous use Initial U.S. Approval: 2023 This product is YUFLYMA (adalimumab-aaty). Adalimumab-aaty is biosimilar* to HUMIRA (adalimumab). | CELLTRION USA, Inc. | 20251028 | 6 |
| These highlights do not include all the information needed to use YUFLYMA safely and effectively. See full prescribing information for YUFLYMA. YUFLYMA (adalimumab-aaty) injection, for subcutaneous use Initial U.S. Approval: 2023 YUFLYMA (adalimumab-aaty) is biosimilar Biosimilar means that the biological product is approved basetd on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences betwe | CELLTRION USA, Inc. | 20251028 | 13 |
| These highlights do not include all the information needed to use ADALIMUMAB-ADAZ safely and effectively. See full prescribing information for ADALIMUMAB-ADAZ. ADALIMUMAB-ADAZ injection, for subcutaneous use Initial U.S. Approval: 2018 This product is HYRIMOZ (adalimumab-adaz). HYRIMOZ (adalimumab-adaz) is biosimilar* to HUMIRA ® (adalimumab). | Sandoz Inc | 20251021 | 15 |
| These highlights do not include all the information needed to use AMJEVITA safely and effectively. See full prescribing information for AMJEVITA. AMJEVITA ® (adalimumab-atto) injection, for subcutaneous use Initial U.S. Approval: 2016 AMJEVITA (adalimumab-atto) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product known as a reference product, and that there are no clinically meaningful differences b | Amgen USA Inc. | Amgen Manufacturing Limited LLC | Amgen, Inc | Charles River Laboratories, Inc. | 20251021 | 14 |
| These highlights do not include all the information needed to use ADALIMUMAB-BWWD safely and effectively. See full prescribing information for ADALIMUMAB-BWWD. ADALIMUMAB-BWWD injection, for subcutaneous use Initial U.S. Approval: 2019 Adalimumab-bwwd is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between th | Cordavis Limited | Samsung Bioepis Co., Ltd. | 20251017 | 2 |
| These highlights do not include all the information needed to use HADLIMA safely and effectively. See full prescribing information for HADLIMA. HADLIMA (adalimumab-bwwd) injection, for subcutaneous use Initial U.S. Approval: 2019 HADLIMA (adalimumab-bwwd) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences betwee | Organon LLC | Samsung Bioepis Co., Ltd. | 20251017 | 13 |
| These highlights do not include all the information needed to use HYRIMOZ ® safely and effectively. See full prescribing information for HYRIMOZ. HYRIMOZ (adalimumab-adaz) injection, for subcutaneous use Initial U.S. Approval: 2018 HYRIMOZ (adalimumab-adaz) is biosimilar* to HUMIRA ® (adalimumab) | Sandoz Inc | 20251017 | 13 |
| These highlights do not include all the information needed to use HYRIMOZ ® safely and effectively. See full prescribing information for HYRIMOZ. HYRIMOZ (adalimumab-adaz) injection, for subcutaneous use Initial U.S. Approval: 2018 HYRIMOZ (adalimumab-adaz) is biosimilar* to HUMIRA ® (adalimumab) | Cordavis Limited | 20251017 | 7 |
| These highlights do not include all the information needed to use SIMLANDI safely and effectively. See full prescribing information for SIMLANDI. SIMLANDI ® (adalimumab-ryvk) injection, for subcutaneous use Initial U.S. Approval: 2024 SIMLANDI (adalimumab-ryvk) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences | A-S Medication Solutions | 20251016 | 1 |
| 168-100-300 Export | Catalent Indiana, LLC | 20250813 | 12 |
| These highlights do not include all the information needed to use YUSIMRY safely and effectively. See full prescribing information for YUSIMRY. YUSIMRY (adalimumab-aqvh) injection, for subcutaneous use Initial U.S. Approval: 2021 YUSIMRY (adalimumab-aqvh) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences betwee | Coherus BioSciences Inc | 20250516 | 6 |
| These highlights do not include all the information needed to use Adalimumab-fkjp safely and effectively. See full prescribing information for Adalimumab-fkjp . Adalimumab-fkjp injection, for subcutaneous use Initial U.S. Approval: 2020 This product is HULIO (Adalimumab-fkjp). HULIO is biosimilar* to HUMIRA (adalimumab) | Biocon Biologics Inc | 20250206 | 4 |
| These highlights do not include all the information needed to use HULIO safely and effectively. See full prescribing information for HULIO . HULIO ® (adalimumab-fkjp) injection, for subcutaneous use Initial U.S. Approval: 2020 HULIO ® (adalimumab-fkjp) is biosimilar* to HUMIRA (adalimumab) | Biocon Biologics Inc | TERUMO YAMAGUCHI CORPORATION | 20250206 | 11 |
| These highlights do not include all the information needed to use ADALIMUMAB-ADBM safely and effectively. See full prescribing information for ADALIMUMAB-ADBM. ADALIMUMAB-ADBM injection, for subcutaneous use Initial U.S. Approval: 2017 This product is CYLTEZO ® (adalimumab-adbm). CYLTEZO (adalimumab-adbm) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that th | QUALLENT PHARMACEUTICALS HEALTH LLC | Boehringer Ingelheim Pharmaceuticals, Inc. | 20241112 | 3 |
| These highlights do not include all the information needed to use IDACIO safely and effectively. See full prescribing information for IDACIO . IDACIO® (adalimumab-aacf) injection, for subcutaneous use Initial U.S Initial U.S. Approval: 2022 IDACIO® (adalimumab-aacf) is biosimilar Guide: Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful | Fresenius Kabi USA, LLC | Merck Serono S.A. | 20241015 | 1 |
| These highlights do not include all the information needed to use HUMIRA safely and effectively. See full prescribing information for HUMIRA. HUMIRA ® (adalimumab) injection, for subcutaneous use Initial U.S. Approval: 2002 | A-S Medication Solutions | 20240516 | 6 |
| These highlights do not include all the information needed to use HADLIMA safely and effectively. See full prescribing information for HADLIMA. HADLIMA (adalimumab-bwwd) injection, for subcutaneous use Initial U.S. Approval: 2019 HADLIMA (adalimumab-bwwd) is biosimilar* to HUMIRA (adalimumab) | A-S Medication Solutions | 20231023 | 3 |
| These highlights do not include all the information needed to use HADLIMA safely and effectively. See full prescribing information for HADLIMA. HADLIMA (adalimumab-bwwd) injection, for subcutaneous use Initial U.S. Approval: 2019 HADLIMA (adalimumab-bwwd) is biosimilar* to HUMIRA (adalimumab) | A-S Medication Solutions | 20231002 | 1 |